The global Digital PCR and Real-time PCR Market is consolidated market. The market is estimated to grow to USD 12.4 billion by 2028 from USD 8.5 billion in 2023, at a CAGR of 7.8%. The growth of this market is due to factors such as the rising incidence and prevalence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies and growing importance of PCR in biomarker discovery.
The global dPCR and qPCR market is highly competitive, with many large, medium-sized, and small market players. The global dPCR and qPCR market was dominated by Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (US), Takara Bio Inc. (Japan), Danaher Corporation (US), Eppendorf (Germany), Promega Corporation (US), Merck KGaA (Germany), QIAGEN (Germany), BioMérieux (France), Meridian Bioscience (US), Quidel Corporation (US), Enzo Biochem, Inc. (US), Stilla (France), Standard BioTools (US), ENDRESS+HAUSER Group Services AG (ENDRESS+HAUSER) (Switzerland), JN Medsys (Singapore), BIONEER CORPORATION (South Korea), ELITech Group (France), QuantaBio (US), Sacace Biotechnologies Srl (Italy), Bio Molecular Systems (Australia), Biomeme, Inc. (US), Kyratec (Australia), LGC Bioresearch Technologies (England), Antylia Scientific (US), and Genome Diagnostics Pvt. Ltd. (India).
To know about the assumptions considered for the study download the pdf brochure
Danaher established itself as a key player in the digital PCR (dPCR) and real-time PCR (qPCR) market in 2022. The firm offers dPCR and qPCR products through its subsidiary companies, Cepheid, Inc., and Beckman Coulter (included under its Life Sciences and Diagnostics business segments). In 2022, it was observed that the company had experienced a boost in its revenue due to the increased sales of its infectious disease testing products such as the Xpert Xpress SARS-CoV-2/Flu/RSV test. However, this exponential growth will not sustain in 2023. To combat this, Danaher strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for this growing market. To remain competitive in the market, the company also focuses on inorganic growth strategies such as agreements and acquisitions. This will further strengthen its presence in the digital PCR (dPCR) and real-time PCR (qPCR) market.
F. HOFFMANN-LA ROCHE LTD.
Roche Diagnostics has established itself as a key player in the digital PCR (dPCR) and real-time PCR (qPCR) market. It strongly invests in R&D activities to improve its existing product portfolio. To remain competitive in the market, the company also focuses on inorganic growth strategies such as agreements and acquisitions. These strategies enable it to expand its point-of-care molecular testing portfolio. The company’s focus on product integration, through the launch of holistic and user-friendly products, will help it to further strengthen its presence in the digital PCR (dPCR) and real-time PCR (qPCR) market.
In 2022, sales of its Molecular Lab (which includes dPCR and qPCR portfolio) business segment dropped due to lower COVID-19-related sales in North America, Europe, and the Middle East & Africa. This was partly offset by growth in the business across its diagnostics solutions for pathogen detection and monitoring, donor screening, sexual health, and genomics.
Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospital, Diagnostic Labs, Pharma, Biotech, CROs) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE